Cboe UK EUR

Recordati Industria Chimica e Farmaceutica S.p.A. (RECM.XC)

51.42

0.00

(0.00%)

At close: January 3 at 4:27:02 PM GMT

Recordati SpA (RICFY) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ...

Recordati SpA (RICFY) reports a 12% revenue increase and confirms full-year targets despite challenges in Turkey and the US market.

GuruFocus.com last month

RICFY

SNY
RECORDATI: CONTINUED DOUBLE-DIGIT GROWTH IN THE FIRST NINE MONTHS OF 2024 - REVENUE +12.0%, EBITDA(1) +11.8%, ADJUSTED NET INCOME(2) +9.5%

Consolidated net revenue of € 1,743.1 million in the first nine months, +12.0% or +9.3% on a like-for-like basis(3) and at constant exchange rates (CER)EBITDA(1) of € 665.7 million, +11.8%, revenue margin of 38.2% Adjusted net income(2) of € 445.4 million, +9.5% Net income of € 338.4 million, +11.1% Free cash flow(4) at € 434.3 million, +€ 42.5 million vs prior yearNet debt(5) at € 1,317.3 million, just below 1.6x EBITDAFinancial targets for FY 2024 confirmed, excluding any potential contributio

GlobeNewswire 2 months ago

RCDTF

RICFY
Recordati SpA (RICFY) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ...

Recordati SpA (RICFY) reports a 30.5% increase in net revenue and upwardly adjusts its full-year financial targets, showcasing robust performance and strategic progress.

GuruFocus.com 3 months ago

RICFY
RECORDATI ANNOUNCES AGREEMENT TO ACQUIRE THE GLOBAL RIGHTS TO ENJAYMO®, STRENGTHENING ITS RARE DISEASES FRANCHISE

Milan, 4th October 2024 – Recordati today announces an agreement with Sanofi to acquire the global rights to Enjaymo® (sutimlimab), a biologic which is the only approved targeted product for the treatment of cold agglutinin disease (CAD), a rare B-cell lymphoproliferative disorder. Enjaymo® (sutimlimab) is a humanized monoclonal antibody indicated for the treatment of hemolysis in adults with CAD. In 2022, it was granted approval by the U.S. Food and Drug Administration (FDA), the European Commi

GlobeNewswire 3 months ago

RCDTF

RICFY

Performance Overview

Return	RECM.XC	FTSE MIB Index
YTD	+0.69%	+2.65%
1-Year	+10.53%	+15.39%
3-Year	+1.85%	+27.06%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Recordati Industria Chimica e Farmaceutica S.p.A. (RECM.XC)

Recordati SpA (RICFY) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ...

RECORDATI: CONTINUED DOUBLE-DIGIT GROWTH IN THE FIRST NINE MONTHS OF 2024 - REVENUE +12.0%, EBITDA(1) +11.8%, ADJUSTED NET INCOME(2) +9.5%

Recordati SpA (RICFY) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ...

RECORDATI ANNOUNCES AGREEMENT TO ACQUIRE THE GLOBAL RIGHTS TO ENJAYMO®, STRENGTHENING ITS RARE DISEASES FRANCHISE

Performance Overview